Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
October 19 2023 - 7:15AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology,
today announced that a late-breaking abstract featuring data for
the company’s NeXT Personal® whole genome-based, tumor-informed
assay for ultra-sensitive ctDNA detection, has been accepted and
selected for a proffered paper presentation at the 2023 European
Society for Medical Oncology (ESMO) Congress, on October 21 in
Madrid, Spain.
Presentation #LBA55
Title: “An ultra-sensitive and specific ctDNA assay
provides novel pre-operative disease stratification in early stage
lung cancer” Location: Salamanca Auditorium - Hall 3
Date: October 21, 2023 Time: 10:15 - 10:25 CEST
Presenter: Dr. James R. Black MD, PhD, Francis Crick
Institute
Late-breaking abstracts are typically reserved for high-quality,
new research findings from randomized phase II or phase III trials
with implications for clinical practice or understanding of disease
processes. Proffered papers are oral presentations of original data
of superior quality, followed by expert discussion and
perspectives.
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest timepoints, enable selection of targeted
therapies based on ultra-comprehensive genomic profiling, and
enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X
(Twitter).
Personalis Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release that are not historical
are “forward-looking statements” within the meaning of U.S.
securities laws, including statements relating to attributes or
advantages of NeXT Personal. Such forward-looking statements
involve known and unknown risks and uncertainties and other factors
that may cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements, including the risks, uncertainties and other factors
that relate to Personalis’ ability to demonstrate attributes or
advantages of NeXT Personal or the Personalis NeXT Platform. These
and other potential risks and uncertainties that could cause actual
results to differ materially from the results predicted in these
forward-looking statements are described under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in Personalis’ Annual Report
on Form 10-K for the year ended December 31, 2022, filed with the
Securities and Exchange Commission (SEC) on February 23, 2023, and
its Quarterly Report on Form 10-Q for the quarter ended June 30,
2023, filed with the SEC on August 8, 2023. All information
provided in this release is as of the date of this press release,
and any forward-looking statements contained herein are based on
assumptions that we believe to be reasonable as of this date. Undue
reliance should not be placed on the forward-looking statements in
this press release, which are based on information available to us
on the date hereof. Personalis undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019417091/en/
Investors: Caroline Corner investors@personalis.com
415-202-5678
Media Contact pr@personalis.com
Personalis (NASDAQ:PSNL)
Historical Stock Chart
From Apr 2024 to May 2024
Personalis (NASDAQ:PSNL)
Historical Stock Chart
From May 2023 to May 2024